Kailo Pharma raises $2.1M
Kailo Pharma announced a Pre-Seed round of $2.1M on 30 March 2026. The company operates in HealthTech and is based in Israel.
Outreach angles
- -Kailo Pharma is developing novel PTSD treatments with pre-seed capital earmarked specifically for advancing toward clinical trials - a clear milestone-driven roadmap rare at this stage.
- -The round was led by NGT HealthCare II with co-investment from the Israel Innovation Authority, combining private and government validation for an early-stage biotech bet.
- -Founded in 2026 and already closing a $2.1M pre-seed round signals rapid institutional interest in a PTSD therapeutic market with limited approved pharmacological options.
Signals
Pre-SeedHealthcareRegulated IndustryDeep Tech
Round details
Company: Kailo Pharma
Domain:
Amount: $2.1M
Stage: Pre-Seed
Industry: HealthTech
Country: Israel
Announced: 30 March 2026
Other HealthTech raises
Recently funded in Israel